follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

NPS Pharmaceuticals appoints new U.S., international presidents

By

Back to Top Comments Email Print

Latest News

    advertisement

    Bedminster-based NPS Pharmaceuticals Inc. announced Tuesday the appointment and promotion of two key executives to support the company’s vision in being a global provider of orphan drugs.

    According to the announcement, Paul Firuta has joined NPS as president, U.S. commercial operations.  He was most recently vice president and general manager at Americas for ViroPharma Inc.  While at ViroPharma, Firuta led the U.S. launch of Cinryze, an orphan biologic product to help patients with hereditary angioedema. The product generated $97 million in sales its first year, making it one of the most successful orphan drug launches in the U.S.

    Eric Pauwels has been promoted to the new position of president, NPS Pharma International and will be responsible for international commercial operations.  He joined NPS in 2011 and has created a commercial team and directed the successful U.S. launch of Gattex, an injection for adult short bowel syndrome, the announcement said.

    ALSO ON NJBIZ:

    SLIDESHOW: NJBIZ Health Care Power 50

    In light of Tesla ban, lawmakers introduce bill allowing direct sales for electric cars

    Coalition takes aim at Waterfront Commission over alleged port worker shortage



    Share This Story On:
    Emily Bader

    Emily Bader

    Emily Bader is the copy and web editor at NJBIZ. She is a Brielle, N.J. native and a Rutgers University alum. You can contact her at emilyb@njbiz.com or @emilybader on Twitter.

    advertisement

    Comments


    Be the first to comment.



    Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

    Post Comment
         View Comment Policy

    Advanced search
    Sponsored by
    advertisement
      
      
    advertisement
      
      
    advertisement
    Back to Top